Roivant Sciences Ltd.
41.81USD
+0.3300 (+0.80%)
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 31.5M | 32.7M | 29.1M | 8.3M | 52.3M | 408.9M |
| Q1 | 4.3M | 21.6M | 8.0M | 2.2M | 1.4M | — |
| Q2 | 12.5M | 3.6M | 4.5M | 1.6M | 3.9M | — |
| Q3 | 17.1M | 15.6M | 9.0M | 2.0M | 11.9M | — |
| Q4 | -2.4M* | 9.0M* | 7.6M* | 2.5M* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | -1.42 | 5.23 | -.240 | -.540 | -1.58 | -1.72 |
| Q1 | -.480 | -.380 | .120 | -.330 | -.260 | — |
| Q2 | -.420 | -.400 | -.310 | -.170 | -.450 | — |
| Q3 | -.490 | 6.03 | .230 | -.380 | -.413 | — |
| Q4 | -.047* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.182* |
| -.285* |
| .437* |
| — |
| — |